Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality
- PMID: 11386890
- DOI: 10.1001/archinte.161.11.1413
Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality
Abstract
Background: Non-high-density lipoprotein cholesterol (non-HDL-C) contains all known and potential atherogenic lipid particles. Therefore, non-HDL-C level may be as good a potential predictor of risk for cardiovascular disease (CVD) as low-density lipoprotein cholesterol (LDL-C).
Objectives: To determine whether non-HDL-C level could be useful in predicting CVD mortality and to compare the predictive value of non-HDL-C and LDL-C levels.
Methods: Data are from the Lipid Research Clinics Program Follow-up Study, a mortality study with baseline data gathered from 1972 through 1976, and mortality ascertained through 1995. A total of 2406 men and 2056 women aged 40 to 64 years at entry were observed for an average of 19 years, with CVD death as the main outcome measure.
Results: A total of 234 CVD deaths in men and 113 CVD deaths in women occurred during follow-up. Levels of HDL-C and non-HDL-C at baseline were significant and strong predictors of CVD death in both sexes. In contrast, LDL-C level was a somewhat weaker predictor of CVD death in both. Differences of 0.78 mmol/L (30 mg/dL) in non-HDL-C and LDL-C levels corresponded to increases in CVD risk of 19% and 15%, respectively, in men. In women, differences of 0.78 mmol/L (30 mg/dL) in non-HDL-C and LDL-C levels corresponded to increases in CVD risk of 11% and 8%, respectively.
Conclusions: Non-HDL-C level is a somewhat better predictor of CVD mortality than LDL-C level. Screening for non-HDL-C level may be useful for CVD risk assessment.
Comment in
-
Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target.Arch Intern Med. 2001 Jun 11;161(11):1379-80. doi: 10.1001/archinte.161.11.1379. Arch Intern Med. 2001. PMID: 11386886 No abstract available.
-
Prediction of cardiovascular mortality.Arch Intern Med. 2002 Jan 14;162(1):108; author reply 109-10. doi: 10.1001/archinte.162.1.108. Arch Intern Med. 2002. PMID: 11784244 No abstract available.
-
The advantages of using non-HDL-C in the diagnosis and treatment of dyslipidemia.Arch Intern Med. 2002 Jan 14;162(1):108-9; author reply 109-10. doi: 10.1001/archinte.162.1.108-a. Arch Intern Med. 2002. PMID: 11784245 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
